- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.04. | CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits | 1 | Zacks | ||
| 16.04. | CVRx, Inc.: CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024 | 1 | GlobeNewswire (USA) | ||
| 16.04. | CVRx has more data supporting long-term benefits of Barostim | 1 | MassDevice | ||
| 15.04. | CVRx, Inc.: CVRx announces availability of additional data supporting long-term benefits of Barostim | 1 | GlobeNewswire (USA) | ||
| 09.02. | CVRx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.01. | Augmedics CEO takes over corner office at CVRx | 2 | MassDevice | ||
| 31.01. | CVRx, Inc.: CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer | 266 | GlobeNewswire (Europe) | Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan.... ► Artikel lesen | |
| 27.01. | CVRx, Inc. (CVRX) Q4 2023 Earnings Call Transcript | 3 | Insider Monkey | ||
| 26.01. | CVRx stock dips despite Street-beating Q4 | 1 | MassDevice | ||
| 26.01. | Analyst Expectations For CVRx's Future | 3 | Benzinga.com | ||
| 25.01. | CVRx Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 25.01. | CVRx: Q4 Earnings Insights | 2 | Benzinga.com | ||
| 25.01. | CVRx, Inc.: CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results | 244 | GlobeNewswire (Europe) | MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions... ► Artikel lesen | |
| 25.01. | CVRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.01. | CVRx GAAP EPS of -$0.44 beats by $0.11, revenue of $11.3M beats by $0.23M | 1 | Seeking Alpha | ||
| 24.01. | Earnings Outlook For CVRx | 2 | Benzinga.com | ||
| 11.01. | CVRx, Inc.: CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024 | 1 | GlobeNewswire (USA) | ||
| 08.01. | CVRx announces CEO retirement, reports Q4 & FY prelim results | 1 | Seeking Alpha | ||
| 08.01. | CVRx, Inc.: CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans | 202 | GlobeNewswire (Europe) | Fourth quarter revenue expected to be $11.2 million to $11.3 million, representing growth of 56% to 58%Full year revenue expected to be $39.2 million to $39.3 million, representing growth of 74% to... ► Artikel lesen | |
| 08.01. | CVRx, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORPEA | 13,614 | +7,48 % | EMEIS PURSUES ITS REFOUNDATION: 2023 Consolidated Financial Results of ORPEA S.A. | Significant improvement in non-financial indicators, with major advances for employees, residents and patients
Health and safety: decline in the work-related accident frequency rate, at 24.8... ► Artikel lesen | |
| NANO-X IMAGING | 8,940 | 0,00 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| BUTTERFLY NETWORK | 0,780 | 0,00 % | ThinkSono Ltd: ThinkSono Releases Real-Time DVT AI Training Solution for Butterfly Network's Handheld Ultrasound Devices | LONDON, ENGLAND / ACCESSWIRE / April 23, 2024 / ThinkSono, a pioneering provider of AI-driven medical imaging solutions, is proud to announce the release of ThinkSono AI Training, a deep vein thrombosis... ► Artikel lesen | |
| GOODRX | 7,190 | 0,00 % | GoodRx Reports Fourth Quarter and Full Year 2023 Results | SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial... ► Artikel lesen | |
| JOINT CORP | 12,230 | 0,00 % | The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results | - Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March... ► Artikel lesen | |
| CARMAT | 3,160 | 0,00 % | CARMAT Announces Its 2023 Annual Results and Provides an Update on Its Progress and Prospects for 2024 | 2023 sales of €2.8 million, i.e. 17 Aeson® implants, including 11 in the last quarter
2024 sales forecast of around €14 million
Active exploration of financing options to extend... ► Artikel lesen | |
| HYPERFINE | 0,845 | 0,00 % | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| PROGYNY | 32,040 | 0,00 % | Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report | ||
| MIMEDX | 6,265 | 0,00 % | Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers | ||
| BIOMERICA | 0,665 | 0,00 % | Biomerica jumps on signing multi-year distribution deal with major UAE healthcare company | ||
| ATRION | 366,00 | -1,08 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
| ATRICURE | 23,170 | 0,00 % | AtriCure upgraded at Oppenheimer on valuation | ||
| TALKSPACE | 3,120 | 0,00 % | Talkspace Announces Third Quarter 2023 Results | B2B payor revenue grew 132% year-over-year 3Q 2023 Operating expenses of $24.0 million, down 30% year-over-year Reduced Net Loss to $4.4 million and Adjusted EBITDA1 loss to $2.8 million, an improvement... ► Artikel lesen | |
| AMWELL | 0,529 | 0,00 % | Amwell Receives Continued Listing Standard Notice From NYSE | Boston, April 04, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of healthcare software as a service, today announced that it received a notice on April 2, 2024 from the New York... ► Artikel lesen | |
| CASTLE BIOSCIENCES | 20,340 | 0,00 % | Castle Biosciences Inc.: Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer | If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes... ► Artikel lesen |
CVRX INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 14,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
